Have a feature idea you'd love to see implemented?
Let us know!
NAUT Nautilus Biotechnology Inc
Price (delayed)
$2.38
Market cap
$298.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.56
Enterprise value
$326M
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics
Highlights
Nautilus Biotechnology's debt has decreased by 11% YoY and by 3.2% QoQ
The quick ratio has contracted by 21% YoY and by 16% from the previous quarter
The equity has decreased by 19% YoY and by 5% from the previous quarter
Key stats
What are the main financial stats of NAUT
Market
Valuations
Earnings
Shares outstanding
125.56M
Market cap
$298.84M
Enterprise value
$326M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.34
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$70.21M
EBITDA
-$63.82M
Free cash flow
-$61.02M
Per share
Balance sheet
Liquidity
EPS
-$0.56
Free cash flow per share
-$0.49
Book value per share
$1.78
Revenue per share
$0
TBVPS
$2.07
Total assets
$259.7M
Total liabilities
$36.27M
Debt
$31.57M
Equity
$223.43M
Working capital
$135.54M
Debt to equity
0.14
Current ratio
16.65
Quick ratio
16.23
Net debt/EBITDA
-0.43
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-24.9%
Return on equity
-28.8%
Return on invested capital
-24.4%
Return on capital employed
-28%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NAUT stock price
How has the Nautilus Biotechnology stock price performed over time
Intraday
1.71%
1 week
-3.25%
1 month
-14.08%
1 year
-11.85%
YTD
-20.4%
QTD
-16.49%
Financial performance
How have Nautilus Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$81.5M
Net income
-$70.21M
Gross margin
N/A
Net margin
N/A
Nautilus Biotechnology's net income has decreased by 17% YoY
Nautilus Biotechnology's operating income has decreased by 12% YoY
Growth
What is Nautilus Biotechnology's growth rate over time
Valuation
What is Nautilus Biotechnology stock price valuation
P/E
N/A
P/B
1.34
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NAUT's EPS is down by 17% year-on-year
The equity has decreased by 19% YoY and by 5% from the previous quarter
The stock's price to book (P/B) is 4.3% less than its last 4 quarters average of 1.4
Efficiency
How efficient is Nautilus Biotechnology business performance
The return on equity has declined by 42% year-on-year and by 6% since the previous quarter
NAUT's return on assets is down by 39% year-on-year and by 6% since the previous quarter
The ROIC is down by 12% year-on-year
Dividends
What is NAUT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NAUT.
Financial health
How did Nautilus Biotechnology financials performed over time
The quick ratio has contracted by 21% YoY and by 16% from the previous quarter
The current ratio fell by 21% YoY and by 15% QoQ
Nautilus Biotechnology's debt is 86% lower than its equity
The equity has decreased by 19% YoY and by 5% from the previous quarter
Nautilus Biotechnology's debt has decreased by 11% YoY and by 3.2% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.